Genus plc operates as an animal genetics company in North America, Latin America, rest of Europe, the Middle East, Russia, Africa, and Asia.
Excellent balance sheet with limited growth.
Share Price & News
How has Genus's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: GNS has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: GNS exceeded the UK Biotechs industry which returned 7.4% over the past year.
Return vs Market: GNS exceeded the UK Market which returned -21.5% over the past year.
Price Volatility Vs. Market
How volatile is Genus's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StDo Institutions Own Shares In Genus plc (LON:GNS)?
1 month ago | Simply Wall StResults: Genus plc Beat Earnings Expectations And Analysts Now Have New Forecasts
1 month ago | Simply Wall StIs Genus (LON:GNS) Using Too Much Debt?
Is Genus undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: GNS (£33.44) is trading above our estimate of fair value (£15.84)
Significantly Below Fair Value: GNS is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: GNS is poor value based on its PE Ratio (56x) compared to the Biotechs industry average (42x).
PE vs Market: GNS is poor value based on its PE Ratio (56x) compared to the UK market (13.3x).
Price to Earnings Growth Ratio
PEG Ratio: GNS is poor value based on its PEG Ratio (5.1x)
Price to Book Ratio
PB vs Industry: GNS is overvalued based on its PB Ratio (4.4x) compared to the GB Biotechs industry average (2.8x).
How is Genus forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GNS's forecast earnings growth (11% per year) is above the savings rate (0.5%).
Earnings vs Market: GNS's earnings (11% per year) are forecast to grow slower than the UK market (15.4% per year).
High Growth Earnings: GNS's earnings are forecast to grow, but not significantly.
Revenue vs Market: GNS's revenue (7.5% per year) is forecast to grow faster than the UK market (2.5% per year).
High Growth Revenue: GNS's revenue (7.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GNS's Return on Equity is forecast to be low in 3 years time (10.1%).
How has Genus performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GNS has a large one-off gain of £25.0M impacting its December 31 2019 financial results.
Growing Profit Margin: GNS became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: GNS's earnings have declined by -12.3% per year over the past 5 years.
Accelerating Growth: GNS has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: GNS has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (14.9%).
Return on Equity
High ROE: GNS's Return on Equity (7.7%) is considered low.
How is Genus's financial position?
Financial Position Analysis
Short Term Liabilities: GNS's short term assets (£211.2M) exceed its short term liabilities (£116.7M).
Long Term Liabilities: GNS's short term assets (£211.2M) do not cover its long term liabilities (£227.2M).
Debt to Equity History and Analysis
Debt Level: GNS's debt to equity ratio (22%) is considered satisfactory.
Reducing Debt: GNS's debt to equity ratio has reduced from 31.7% to 22% over the past 5 years.
Debt Coverage: GNS's debt is well covered by operating cash flow (44.9%).
Interest Coverage: GNS's interest payments on its debt are well covered by EBIT (4.2x coverage).
What is Genus's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: GNS's dividend (0.83%) isn’t notable compared to the bottom 25% of dividend payers in the UK market (2.49%).
High Dividend: GNS's dividend (0.83%) is low compared to the top 25% of dividend payers in the UK market (6.84%).
Stability and Growth of Payments
Stable Dividend: GNS is not paying a notable dividend for the UK market, therefore no need to check if payments are stable.
Growing Dividend: GNS is not paying a notable dividend for the UK market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: GNS is not paying a notable dividend for the UK market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of GNS's dividend in 3 years as they are not forecast to pay a notable one for the UK market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Stephen Wilson (59yo)
Mr. Stephen Wilson serves as Chief Executive Officer and Director of Genus plc since September 13, 2019. Mr. Wilson served as Group Finance Director of Genus plc since March 1, 2013 and served as its Execu ...
CEO Compensation Analysis
Compensation vs Market: Stephen's total compensation ($USD1.88M) is about average for companies of similar size in the UK market ($USD2.44M).
Compensation vs Earnings: Stephen's compensation has been consistent with company performance over the past year.
|CEO & Director||0.58yr||UK£1.51m||0.11% £2.4m|
|CFO & Director||0.25yr||no data||no data|
|Chief Operating Officer||no data||no data||0.10% £2.2m|
|Head of R&D and Chief Scientific Officer||0.75yr||no data||no data|
|Group General Counsel & Company Secretary||5.83yrs||no data||0.093% £2.0m|
|Group Human Resources Director||2.75yrs||no data||no data|
|Chief Operating Officer of Genus ABS Beef||7.75yrs||no data||no data|
|Chief Operating Officer of Genus ABS Dairy||3.17yrs||no data||no data|
|Group Financial Controller||no data||no data||no data|
Experienced Management: GNS's management team is considered experienced (2.8 years average tenure).
|CEO & Director||0.58yr||UK£1.51m||0.11% £2.4m|
|CFO & Director||0.25yr||no data||no data|
|Independent Non-Executive Director||1.75yrs||UK£55.00k||no data|
|Senior Independent Non-Executive Director||1.42yrs||UK£57.00k||0.0031% £66.6k|
|Independent Non-Executive Chairman||9.42yrs||UK£171.00k||0.013% £285.3k|
|Non-Executive Director||5.75yrs||UK£60.00k||0.0058% £125.1k|
|Independent Non-Executive Director||4yrs||UK£61.00k||no data|
Experienced Board: GNS's board of directors are considered experienced (4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.4%.
Genus plc's company bio, employee growth, exchange listings and data sources
- Name: Genus plc
- Ticker: GNS
- Exchange: LSE
- Founded: 1994
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: UK£2.156b
- Shares outstanding: 64.68m
- Website: https://www.genusplc.com
Number of Employees
- Genus plc
- Matrix House
- Basing View
- RG21 4DZ
- United Kingdom
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|GNS||LSE (London Stock Exchange)||Yes||Ordinary Shares||GB||GBP||Jan 1998|
|GENS.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Jan 1998|
|GBE||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Jan 1998|
|GNSL||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Ordinary Shares||GB||GBP||Jan 1998|
Genus plc operates as an animal genetics company in North America, Latin America, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates in three segments: Genus PIC, Genus ABS, and Research and Development. It sells sows, boars, and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands. In addition, it offers semen sexing, in vitro fertilization, reproductive, and other technical services to farmers. The company has a strategic porcine collaboration with Beijing Capital Agribusiness Co. Ltd to research, develop, register, and market porcine reproductive and respiratory syndrome virus resistant pigs. Genus plc was incorporated in 1994 and is based in Basingstoke, the United Kingdom.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/09 21:05|
|End of Day Share Price||2020/04/09 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.